OncoImmunology · 2017 · 13 citations · 33 references
Life SciencesHematologyImmunologyCancer ImmunologyClinical ImmunologyImmunotherapyB Cell ActivationB Cell BiologyB Cell RegulationB-cell ResponsesCancer ImmunotherapyHumoral ImmunityAntibody Repertoire SequencingB Cell RecoveryB Cell Repertoire DiversityB Cell Repertoire FormationB-cell Repertoire AnalysisBruton Tyrosine KinaseBruton's Tyrosine Kinase InhibitorsFlow Cytometry Immunophenotyping
. This pattern is compatible with a deletion of pre-existing antigen-experienced B cells followed by repertoire renewal with antigen-naïve B cells. These opposite patterns in B cell dynamics may result in different responses towards neoantigens versus recall antigens, which need to be further defined.
33
PARTITIONING DIVERSITY INTO INDEPENDENT ALPHA AND BETA COMPONENTS
Lou Jost · Ecology · 2007 · 2.3K citations
Life Sciences, Biology, Ecology +17
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts, Matthew S. Davids, John M. Pagel et al. · New England Journal of Medicine · 2015 · 1.9K citations · Full text
Medicine, Cancer Biology, Oncology +14
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
John C. Byrd, Jennifer R. Brown, Susan O’Brien et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text
Medicine, Hematology, Oncology +17
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Jan A. Burger, Alessandra Tedeschi, Paul M. Barr et al. · New England Journal of Medicine · 2015 · 1.6K citations · Full text
Medicine, Oncology, Pharmacotherapy +11